ImmunoPrecise acquisition boosts antibody service

By Flora Southey contact

- Last updated on GMT

iStock/designer491
iStock/designer491
ImmunoPrecise Antibodies has acquired U-Protein Express, enabling it to offer microgram quantities of engineered antibodies to clients.

Under the terms of the agreement, Vancouver, Canada-based ImmunoPrecise will purchase U-Protein’s equipment, staff and client base for a combined cash and stock value of €6.83m ($10.32m).

ImmunoPrecise, which offers antibody engineering and production services including the development of mouse and rat monoclonal, and rabbit recombinant monoclonal antibodies, will employ U-Protein’s technologies to manufacture microgram quantities of ImmunoPrecise-engineered antibodies.

U-Protein provides mammalian recombinant proteins and antibodies for clients’ research and pre-clinical applications, and holds the rights to proprietary expression technology used in antibody production.

 “U-Protein Express can take ​[our] antibodies and grow them in their cell lines to delivery gram quantities to our customers,” ​said CEO Tom D’Ozario.

“For many of our clients, this expression of antibodies is a natural step in product development,” ​he added.

New clients, new market

D’Orazio told us he anticipates the acquisition will attract business, and diversify the firm’s revenue base.

“We have already seen a company become more interested in using us for contract research, once they found out we could be a one-stop-shop for more services,” ​he told us.

The acquisition of Utrecht, The Netherlands-based U-Protein, enables ImmunoPrecise to expand into the European marketplace, D’Ozario added.

“We foresee both commercial and technical expansion opportunities,” ​he said.

Related topics: Contract Manufacturing

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers